Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Часто задаваемые вопросы
В каком секторе работает Cytokinetics, Incorporated (CYTK)?
Cytokinetics, Incorporated относится к сектору Здравоохранение.
Какова текущая цена акций Cytokinetics, Incorporated (CYTK)?
По последним данным, цена акций Cytokinetics, Incorporated составляет 74,13 $, предыдущее закрытие — 73,45 $. За последнюю торговую сессию акции Cytokinetics, Incorporated выросли на 0,68 $, что соответствует росту на 0,93%.
Выплачивает ли Cytokinetics, Incorporated (CYTK) дивиденды?
Нет, Cytokinetics, Incorporated не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Cytokinetics, Incorporated (CYTK)?
У компании Cytokinetics, Incorporated бета 0.376, что указывает на более низкую волатильность по сравнению с рынком в целом.
